Meta-analysis of the plasminogen activator inhibitor-1 (PAI-1) gene with insertion/deletion 4G/5G polymorphism and its susceptibility to ischemic stroke in Thai population

1. Yamada Y. Identification of genetic factors and development of genetic risk diagnosis systems for cardiovascular diseases and stroke. Circ. 2006; 70: 1240-8.10.1253/circj.70.1240Open DOISearch in Google Scholar

2. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119:e21-81.10.1161/CIRCULATIONAHA.108.191261Search in Google Scholar

3. Xu X, Li J, Sheng W, Liu L. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis. 2008; 26:48-62.10.1159/000135653Open DOISearch in Google Scholar

4. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ. A navigator for human genome epidemiology. Nat Genet. 2008; 40:124-5.10.1038/ng0208-124Open DOISearch in Google Scholar

5. Van Goor ML, Garcia EG, Leebeek F, Brouwers GJ, Koudstaal P, Dippel D. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. Thromb Haemost. 2005; 93:92-6.10.1160/TH04-09-0560Search in Google Scholar

6. Tsantes AE, Nikolopoulos GK, Bagos PG, Tsiara CG, Kapsimali V, Travlou A, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis. Blood Coagul Fibrinolysis. 2007; 18:497-504.10.1097/MBC.0b013e3281ec4eeeSearch in Google Scholar

7. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis. 2001; 11:294-9.10.1159/000047656Search in Google Scholar

8. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993; 268: 10739-45.10.1016/S0021-9258(18)82047-6Search in Google Scholar

9. Ding J, Nicklas BJ, Fallin MD, de Rekeneire N, Kritchevsky SB, Pahor M, et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J. 2006; 152:1109-15.10.1016/j.ahj.2006.06.02117161063Search in Google Scholar

10. Eriksson P, Kallin B, van ‘t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995; 92:1851-5.10.1073/pnas.92.6.1851423807892190Search in Google Scholar

11. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost. 1998; 79: 975-9.10.1055/s-0037-1615105Search in Google Scholar

12. Zoller B, Garcia de Frutos P, Dahlback B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemost. 1998; 79:802-7.10.1055/s-0037-1615068Search in Google Scholar

13. Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thrombosis Research. 2008; 122:736-42.10.1016/j.thromres.2007.09.00517949795Search in Google Scholar

14. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001; 104:3063-8.10.1161/hc5001.10079311748101Open DOISearch in Google Scholar

15. Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke. 2005; 36: 1661-5.10.1161/01.STR.0000174485.10277.2416020771Search in Google Scholar

16. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost. 1997; 77:730-4.10.1055/s-0038-1656042Search in Google Scholar

17. Endler G, Lalouschek W, Exner M, Mitterbauer G, Haring D, Mannhalter C. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol. 2000; 110:469-71.10.1046/j.1365-2141.2000.02164.x10971410Search in Google Scholar

18. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT, Reiner AP. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 2002; 9:131-7.10.1177/17418267020090020912006921Search in Google Scholar

19. Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke. 2003; 34:2822-8.10.1161/01.STR.0000098004.26252.EB14605330Search in Google Scholar

20. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation. 2000; 101:67-70.10.1161/01.CIR.101.1.6710618306Open DOISearch in Google Scholar

21. Tsantes AE, Nikolopoulos GK, Bagos PG, Rapti E, Mantzios G, Kapsimali V, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A metaanalysis. Thromb Haemost. 2007; 97:907-13.10.1160/TH06-12-0745Search in Google Scholar

22. Attia J, Thakkinstian A, Wang Y, Lincz L, Parsons M, Sturm J, et al. The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and metaanalysis. J Stroke Cerebrovasc Dis. 2007; 16:173-9.10.1016/j.jstrokecerebrovasdis.2007.03.002Search in Google Scholar

23. Akar N, Akar E, Yilmaz E, Deda G. Plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation. J Child Neurol. 2001; 16:294-5.10.1177/088307380101600413Search in Google Scholar

24. Ando R, Doi M, Yamauchi K, Chida Y, Ida T, Endo K, Yanagi H, Tomura S. Association of beta-fibrinogen and factor VII polymorphism with plasma fibrinogen and factor VII levels, and no association of PAI-1 polymorphism with plasma PAI-1 levels in hemodialysis patients. Clin Nephrol. 2002; 58:25-32.10.5414/CNP58025Search in Google Scholar

25. Arlestig L, Wallberg Jonsson S, Stegmayr B, Rantapaa- Dahlqvist S. Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007; 25:866-71.Search in Google Scholar

26. Austin H, Chimowitz MI, Hill HA, Chaturvedi S, Wechsler LR, Wityk RJ, et al. Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. Stroke. 2002; 33:2762-8.10.1161/01.STR.0000038094.79901.3BOpen DOISearch in Google Scholar

27. Boncoraglio GB, Bodini A, Brambilla C, Carriero MR, Ciusani E, Parati EA. An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke. Cerebrovasc Dis. 2006; 22:191-5.10.1159/000093604Search in Google Scholar

28. Chen CH, Eng HL, Chang CJ, Tsai TT, Lai ML, Chen HY, et al. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J Lab Clin Med. 2003; 142:100-5.10.1016/S0022-2143(03)00063-5Search in Google Scholar

29. Elbaz A, Cambien F, Amarenco P. Plasminogen activator inhibitor genotype and brain infarction. Circulation. 2001; 103, e13-14; author reply e13-14.Search in Google Scholar

30. Guan WJ, Wang JX. Effect of gene polymorphism of the PAI-1 gene promoter region on patients with essential hypertension complicated by cerebral infarction. Zhong Hua Lao Nian Yi Xue Za Zhi. 2004; 10:765-8.Search in Google Scholar

31. Jood K, Ladenvall P, Tjarnlund-Wolf A, Ladenvall C, Andersson M, Nilsson S, et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke. 2005; 36: 2077-81.10.1161/01.STR.0000183617.54752.6916179568Open DOISearch in Google Scholar

32. Kain K, Young J, Bamford J, Bavington J, Grant PJ, Catto AJ. Determinants of plasminogen activator inhibitor-1 in South Asians with ischaemic stroke. Cerebrovasc Dis. 2002; 14:77-83.10.1159/00006473212187010Search in Google Scholar

33. Komitopoulou A, Platokouki H, Kapsimali Z, Pergantou H, Adamtziki E, Aronis S. Mutations and polymorphisms in genes affecting hemostasis proteins and homocysteine metabolism in children with arterial ischemic stroke. Cerebrovasc Dis. 2006; 22:13-20.10.1159/00009233216567932Open DOISearch in Google Scholar

34. Lee C, Kong M. An interactive association of common sequence variants in the neuropeptide Y gene with susceptibility to ischemic stroke. Stroke. 2007; 38: 2663-9.10.1161/STROKEAHA.107.48207517702963Open DOISearch in Google Scholar

35. Nowak-Göttl U, Sträter R, Kosch A, von Eckardstein A, Schobess R, Luigs P, et al. The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population infarction. Nao Yu ShenJing Ji Bing Za Zhi. 2001; 9: 323-6.Search in Google Scholar

36. Petrovic D, Milanez T, Kobal J, Bregar D, Potisk KP, Peterlin B. Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction. Acta Neurol Scand. 2003; 108:109-13.10.1034/j.1600-0404.2003.00126.x12859287Open DOISearch in Google Scholar

37. Reiner AP, Schwartz SM, Frank MB, Longstreth WT, Hindorff LA, Teramura G, et al. Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. Stroke. 2001; 32:2580-6.10.1161/hs1101.09815011692020Open DOISearch in Google Scholar

38. Saidi S, Slamia LB, Mahjoub T, Ammou SB, Almawi WY. Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1/tPA levels in stroke: a case-control study. J Stroke Cerebrovasc Dis. 2007; 16:153-9.10.1016/j.jstrokecerebrovasdis.2007.02.00217689411Search in Google Scholar

39. Sirgo G, Perez-Vela JL, Morales P, Del Rey M, Vendrell J, Gutierrez C, et al. Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery. Intensive Care Med. 2006; 32:668-75.10.1007/s00134-006-0092-y16508752Search in Google Scholar

40. Sun Q, Zhang YD, Liu Y. The study of plasma PAI-1 activity and its gene polymorphism in cerebral Luther T, Breier G, et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci. 1997; 811:191-206.10.1111/j.1749-6632.1997.tb52002.x9186598Search in Google Scholar

41. Xu BZC, Xian BX. A study of the plasma plasminogen activator inhibitor-1 activity and its promoter region 4G/5G gene polymorphism in acute cerebral infarction, Zhong Guo Yi Shi Jin Xiu Za Zhi. 2006; 29:26-8.Search in Google Scholar

42. Yeh PS, Lin HJ, Li YH, Lin KC, Cheng, TJ, Chang CY, Ke DS. Prognosis of young ischemic stroke in Taiwan: impact of prothrombotic genetic polymorphisms. Thromb Haemost. 2004; 92:583-9.10.1160/TH04-03-009915351855Search in Google Scholar

43. Zee RY, Cook NR, Cheng S, Reynolds R, Erlich HA, Lindpaintner K, Ridker PM. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet. 2004; 13:389-96.10.1093/hmg/ddh03914681304Search in Google Scholar

44. Zhan M, Zhou Y, Han Z. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin Med J. 2003; 116:1707-10.Search in Google Scholar

45. Zhang SB, Wang JX. The associationof PAI-1 4G/5G polymorphismwith cerebral infarction. Shan Dong Yi Yao. 2003; 43:42-3.Search in Google Scholar

46. Zhang C, Li J, Li L, Luo B. The study of PAI-1 promotor region gene polymorphism in cerebrovascular disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2001; 18:383-7.Search in Google Scholar

47. Zhang YDSQ, Liu Y. The association of PAI-1 gene polymorphism with cerebral infarction and recurrent cerebral infarction. Lin Chuang Shen Jing Bing Xue Za Zhi. 2001; 14:262-5.Search in Google Scholar

48. Yi G. A study of the plasma plasminogenactivator inhibitor-1 activity and its promoterregion gene polymorphism in acute cerebralinfarction., Qing Dao Da Xue Yi XueYuan Xue Bao. 2004; 40:229-31.Search in Google Scholar

49. Crainich PJN, Tang Z, Arnold AM, Kuller LH, Manolio T. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost. 2003;1 :1799-804.10.1046/j.1538-7836.2003.00255.x12911596Search in Google Scholar

50. Kucukarabaci B, Gunes HV, Ozdemir G, Cosan D, Ozbabalik D, Dikmen M, Degirmenci I. Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke. Genet Test12.2008; xxx: 443-51.10.1089/gte.2008.002518662099Search in Google Scholar

51. Crainich P, Jenny NS, Tang, Z, Arnold AM, Kuller LH, Manolio T, et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost1. 2003;1799-1804.10.1046/j.1538-7836.2003.00255.xSearch in Google Scholar

52. Nilsson L, Gafvels M, Musakka L, Ensler K, Strickland DK, Angelin B, et al. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor. J Lipid Res. 1999; 40:913-9.10.1016/S0022-2275(20)32126-XSearch in Google Scholar

53. Van Hinsbergh VW, Kooistra T, Van den Berg EA, Princen HM, Fiers W, Emeis, JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 1988; 72:1467-73.10.1182/blood.V72.5.1467.1467Search in Google Scholar

54. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk.Search in Google Scholar

Thromb Haemost. 2004; 91:861-72.10.1160/TH03-08-0546Search in Google Scholar

55. Vergouwen MD, Frijns CJ, Roos YB, Rinkel GJ, Baas F, Vermeulen M. Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke. 2004; 35:1280-3.10.1161/01.STR.0000128707.48644.7eSearch in Google Scholar

56. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006; 367: 651-8.10.1016/S0140-6736(06)68263-9Search in Google Scholar

57. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev. 2008; 16:192-201.10.1002/1520-7560(200005/06)16:3<192::AID-DMRR114>3.0.CO;2-GSearch in Google Scholar

58. Sartori MT, Vettor R, De Pergola G, De Mitrio V, Saggiorato G, Della Mea P, et al. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance. Thromb Haemost. 2001; 86:1161-9.10.1055/s-0037-1616045Search in Google Scholar

59. Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost. 1998; 80: 1029-30.10.1055/s-0037-1615408Search in Google Scholar

60. Benchenane K, Lopez-Atalaya JP, Fernandez- Monreal M, Touzani O, Vivien D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 2004; 27:155-60.10.1016/j.tins.2003.12.011Open DOISearch in Google Scholar

61. Underwood MJ, De Bono DP. Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price. Cardiovasc Res. 1993; 27:882-5.10.1093/cvr/27.5.8828348588Open DOISearch in Google Scholar

62. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999; 5:1135-42.10.1038/1345910502816Search in Google Scholar

63. Carmeliet P, Moons L, Dewerchin M, Mackman N, of Germanchildren. Eur J Hematol. 2001; 66:57-62.Search in Google Scholar

64. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation. 1999; 99: 2440-4.10.1161/01.CIR.99.18.244010318667Open DOISearch in Google Scholar

65. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000; 342:1792-801.10.1056/NEJM20000615342240610853003Search in Google Scholar

66. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24:35-41.10.1161/01.STR.24.1.357678184Open DOISearch in Google Scholar

67. Han S, Li Y, Mao Y, Xie Y. Meta-analysis of the association of CTLA-4 exon-1 +49A/G polymorphism with rheumatoid arthritis. Hum Genet. 2005; 118: 123-32. 10.1007/s00439-005-0033-916133179Search in Google Scholar